Skip to main content

Table 3 Associations of HER2 and TOP2A with ER, PgR and Ki67 status (assessed by IHC)

From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

  ER status   PgR status   Ki67 status  
  Negative Positive p Negative Positive p Low High p
  N (%) N (%)   N (%) N (%)   N (%) N (%)  
HER2 (CISH)    < 0.001    0.001    0.035
   Non-amplified 47 (61.8) 173 (83.2)   63 (65.6) 156 (83.4)   42 (89.4) 176 (75.2)  
   Amplified 29 (38.2) 35 (16.8)   33 (34.4) 31 (16.6)   5 (10.6) 58 (24.8)  
HER2 (mRNA)    < 0.001    < 0.001    0.086
   Low (< 75th perc) 38 (55.9) 166 (82.6)   53 (59.6) 151 (84.4)   40 (87.0) 168 (74.0)  
   High (≥ 75th perc) 30 (44.1) 35 (17.4)   36 (40.4) 28 (15.6)   6 (13.0) 59 (26.0)  
HER2 (IHC)    0.003    0.002    0.016
   0-1+ 47 (58.8) 163 (75.5)   61 (58.7) 148 (77.5)   43 (87.8) 163 (67.4)  
   2+ 9 (11.3) 25 (11.6)   15 (14.4) 19 (9.9)   3 (6.1) 31 (12.8)  
   3+ 24 (30.0) 28 (13.0)   28 (26.9) 24 (12.6)   3 (6.1) 48 (19.8)  
TOP2A (CISH)    0.29    0.46    0.33
   Non-amplified 64 (90.1) 182 (93.8)   83 (91.2) 162 (93.6)   41 (97.6) 202 (91.8)  
   Amplified 7 (9.9) 12 (6.2)   8 (8.6) 11 (6.4)   1 (2.4) 18 (8.2)  
TOP2A (mRNA)    0.99    0.20    0.003
   Low (< median) 34 (50.0) 100 (49.8)   39 (43.8) 94 (52.5)   33 (71.7) 107 (47.1)  
   High (≥ median) 34 (50.0) 101 (50.2)   50 (56.2) 85 (47.5)   13 (28.3) 120 (52.9)  
TopoIIa (IHC)    0.39    0.99    < 0.001
   Negative 29 (40.3) 69 (34.5)   33 (35.9) 64 (35.8)   32 (78.0) 66 (28.8)  
   Positive 43 (59.7) 131 (65.5)   59 (64.1) 115 (64.2)   9 (22.0) 163 (71.2)